Wockhardt to exit US generic pharma segment to unlock capital for high-impact areas

Wockhardt to exit US generic pharma segment to unlock capital for high-impact areas

Trade

• Watchlist
• Portfolio
• Message
• Set Alert

 

 

Choose Stock Exchange: BSE LIVE NSE LIVE

26 Aug, 2025 12:21

Volume

Todays L/H

More

×

Wockhardt Ltd on July 11 said it has decided to exit US generic pharmaceutical segment to unlock capital for high-impact areas.

"Wockhardt is undertaking significant strategic realignment of its US business in line with its long-term vision to build a differentiated, innovation-driven pharmaceutical enterprise. As part of this transition, the Company has taken decision to exit the US generic pharmaceutical segment, paving the way for deeper focus and investment in its advanced product portfolio," said the company in a stock exchange filing.

"This strategic reset aligns with Wockhardt’s sharpened focus on building a future-ready business anchored in two key pillars:
1. New Antibiotic Drug Discovery – where Wockhardt has established a leadership position globally, with a strong pipeline of differentiated assets.
2. Biologicals Portfolio in Insulin – leveraging advanced technologies to address critical unmet needs in diabetes care," the company added.

Wockhardt said its US generics business has been incurring losses over the past several years. In FY 2025 alone, the generics business incurred a loss of nearly $8 million, it said.

Accordingly, Wockhardt has filed for voluntary liquidation under Chapter 7 of the US Bankruptcy Code for its US step down subsidiaries, Morton Grove Pharmaceuticals Inc. and Wockhardt USA LLC, both incorporated in Delaware which are wholly owned subsidiaries of Wockhardt Bio AG. This decision, effective 11 July 2025, enables a clean and structured exit from a legacy segment and unlocks management bandwidth and capital for high-impact areas.

The company said it remains committed to its pharmaceutical operations in India, the UK, Ireland, and other geographies where its businesses continue to deliver strong performance.

On July 11, Wockhardt Ltd's shares on BSE closed 3.5% higher at Rs 1,756 apiece.